SERO’s Derek McHaffie Presented Radium 223 Dichloride in Treatment of Castration Resistant Metastatic Prostate Cancer

Written By: Dr. Derek McHaffie

Derek McHaffie, MD, a SERO physician with expertise across the spectrum of prostate cancer care, presented retrospective data from the Levine Cancer Institute’s experience with Radium 223 Dichloride (Xofigo) in the treatment of castration resistant metastatic prostate cancer at the 56th annual meeting of the American Society of Radiation Oncology in San Francisco, CA.